Aminoglycoside antibiotics are the most common cause of antibiotic-related ototoxicity, but they aren’t the only class that can damage your hearing. Macrolides, vancomycin, and even certain antibiotic ear drops carry risk under specific circumstances. The type of damage, whether it’s reversible, and which part of the ear is affected all depend on the drug involved.
Aminoglycosides: The Highest-Risk Class
Aminoglycosides are the antibiotics most strongly linked to permanent hearing loss and balance problems. The drugs in this class include gentamicin, tobramycin, amikacin, streptomycin, neomycin, kanamycin, and netilmicin. They’re typically given intravenously for serious infections like sepsis, complicated urinary tract infections, and tuberculosis.
Not all aminoglycosides damage the ear in the same way or to the same degree. Neomycin is considered the most toxic. Gentamicin, kanamycin, and tobramycin fall in the middle. Amikacin and netilmicin carry the lowest ototoxic risk within this class. The specific part of the inner ear affected also varies: streptomycin and gentamicin primarily damage the vestibular system (your balance organs), while amikacin, neomycin, and kanamycin tend to damage the cochlea (your hearing organ). Tobramycin affects both equally.
The damage happens because aminoglycosides cross from the bloodstream into the fluid-filled chambers of the inner ear. Once there, they enter the sensory hair cells through tiny channels on the cell surface that normally let in calcium. The problem is that once aminoglycosides get inside a hair cell, they essentially become trapped. They can’t exit the way they came in. Inside the cell, they disrupt electrical signaling and trigger cell death. The destruction typically starts with the hair cells responsible for detecting high-pitched sounds, then gradually moves toward lower frequencies. Because these hair cells don’t regenerate in humans, the hearing loss is usually permanent.
Macrolides: Usually Temporary
Macrolide antibiotics, including erythromycin, clarithromycin, and azithromycin, can cause hearing changes, but the pattern is very different from aminoglycosides. The damage is typically reversible. In a systematic review of reported cases, hearing improved after stopping the drug in 70 out of 78 patients, with recovery occurring within hours to days. Most cases resolve fully within one to three weeks of stopping treatment.
Tinnitus (ringing in the ears) appears to be the more persistent problem with macrolides. Research shows a dose-dependent relationship: the association with tinnitus becomes statistically significant at cumulative doses of 14 or more defined daily doses. Very recent use (within three weeks) tends to raise hearing thresholds, but that effect fades after the drug clears the body. Tinnitus, however, may linger even after hearing levels return to normal.
Vancomycin: Debated but Real
Vancomycin, a glycopeptide antibiotic used for serious infections like MRSA, has an estimated ototoxicity incidence of around 12%, roughly double what older estimates suggested. Interestingly, the risk doesn’t appear to correlate with blood levels of the drug, which makes it harder to predict who will be affected. This is an unusual pattern compared to aminoglycosides, where higher drug concentrations generally mean higher risk. The concern with vancomycin grows substantially when it’s given alongside other ear-damaging medications.
Antibiotic Ear Drops and Perforated Eardrums
Aminoglycoside-containing ear drops, particularly those with gentamicin or neomycin, are safe when the eardrum is intact. The eardrum acts as a barrier, preventing the drug from reaching the inner ear. If you have a perforated eardrum or ear tubes, however, the situation changes significantly. The antibiotic can pass through the perforation into the middle ear space and from there reach the inner ear.
Reports document cases of both hearing loss and vestibular damage in patients who used gentamicin-containing drops with perforated eardrums, sometimes after as few as 16 days of use. Long-term use over months or years carries even greater risk. For patients with perforations or tubes, fluoroquinolone drops like ciprofloxacin or ofloxacin are considered safer alternatives. They carry a lower ototoxicity risk and are equally or more effective at treating ear infections. When aminoglycoside drops are necessary in patients with perforations, guidelines recommend limiting use to two weeks or less and only when there’s an active infection.
Medications That Multiply the Risk
Certain drugs dramatically increase the ototoxic potential of antibiotics when given at the same time. Loop diuretics (used to treat fluid retention and high blood pressure) are the most important example. These diuretics temporarily lower the electrical charge inside the inner ear’s fluid compartment by blocking a specific ion transporter in the tissue that maintains inner ear chemistry. On their own, this effect is reversible. But when an aminoglycoside is present in the bloodstream at the same time, the diuretic essentially opens the door for the antibiotic to flood into the inner ear at much higher concentrations. Once the diuretic’s effect wears off and the barrier is restored, the aminoglycoside becomes trapped inside, causing permanent damage to both the structure and function of the cochlea.
Noise exposure during aminoglycoside treatment also acts synergistically, meaning the combined damage is worse than either factor alone.
A Genetic Variant That Changes Everything
Some people carry a mitochondrial DNA mutation called A1555G in the MT-RNR1 gene that makes them extraordinarily sensitive to aminoglycosides. Carriers of this mutation can develop severe, irreversible hearing loss or complete deafness after even a single course of treatment.
The prevalence varies by population: roughly 2.9% to 5.3% in Asian populations, 0.6% to 2.5% in Caucasian populations, and as high as 17% among Spanish individuals with unexplained hearing loss. Among people who are deaf and have a history of aminoglycoside exposure, 15% to 30% carry this variant. Genetic testing before aminoglycoside treatment could identify these individuals, but widespread screening isn’t yet standard practice.
Recognizing the Early Signs
Ototoxicity can affect hearing, balance, or both, and the symptoms depend on which part of the inner ear is involved.
Cochlear damage (hearing) typically starts at the highest frequencies, well above the range of normal conversation. You might first notice tinnitus, a feeling of fullness in the ears, or difficulty hearing certain sounds like birdsong or alarm tones. Because the earliest damage occurs above 8,000 Hz, standard hearing tests can miss it. Extended high-frequency testing up to 20,000 Hz is more sensitive for catching changes early.
Vestibular damage (balance) shows up as dizziness, unsteadiness when walking, or oscillopsia, a sensation that the world bounces or blurs when you move your head. These symptoms can be subtle at first, especially if both ears are affected equally, because you may unconsciously compensate by relying more on your vision and body position sense.
Monitoring During Treatment
For anyone receiving aminoglycoside antibiotics, current guidelines recommend a baseline hearing test within 72 hours of starting treatment, followed by repeat testing every two to three days or at minimum weekly for the duration of therapy. After the antibiotic course ends, follow-up testing is recommended immediately, then again at three and six months, since damage can continue to progress even after the drug is stopped. If any change in hearing is detected, retesting should happen at least weekly until levels stabilize.
In practice, many treatment sites test less frequently than guidelines recommend. If you’re receiving aminoglycosides or vancomycin and haven’t been offered hearing monitoring, it’s worth asking about it. Early detection of a hearing shift gives your care team the chance to adjust treatment before the damage reaches frequencies that affect everyday communication.
Protective Strategies Under Investigation
Several compounds show promise for protecting the inner ear during aminoglycoside therapy. Aspirin currently has the most consistent evidence of protecting against gentamicin-related hearing loss in clinical settings. N-acetylcysteine (NAC), a supplement also used as a medication, has shown benefit specifically in dialysis patients receiving aminoglycosides. A compound called ORC-13661, which works by physically blocking the channel that aminoglycosides use to enter hair cells, is the most advanced drug in development specifically designed to prevent this type of damage. Other approaches being studied include antioxidants like vitamin C and compounds that stabilize the energy-producing structures inside hair cells.